$CLDX News

Celldex Therapeutics (CLDX) Stock Looks Rich After Shareholder Investigation

Celldex Therapeutics: Trying To Put Its Troubled History Behind It

HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $64 Price Target

Can Celldex (CLDX) Overcome Its Heavy Burn Rate for Long-Term Success?

Leerink Partners Maintains Outperform on Celldex Therapeutics, Raises Price Target to $88

Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $57

CLDX Stock Slumps 11% – This Analyst Sees Nearly 90% Upside, Calls Phase 3 Trial Safety Concerns ‘Misplaced’

Celldex Phase III CSU Trials Hit Endpoints as Barzolvolimab Shows Durable Responses

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria Transcript

Celldex Therapeutics, Inc. (CLDX) Discusses Positive Phase 3 Results for Barzolvolimab in Chronic Spontaneous Urticaria - Slideshow

Celldex Shares Rise 8% as Barzolvolimab Meets Primary Endpoints in Two Phase 3 Trials

HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Raises Price Target to $64

Cantor Fitzgerald Maintains Overweight on Celldex Therapeutics, Raises Price Target to $72

Celldex Therapeutics' Barzolvolimab Meets Phase 3 Endpoints in Two Urticaria Trials

Celldex Announces Positive Results from Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Studies of Barzolvolimab Which Met Primary and All Key Secondary Endpoints

Celldex Reports Topline Results From The Company’s Phase 3 EMBARQ-CSU1 and EMBARQ-CSU2 Trials Evaluating Two Doses Of Barzolvolimab In Patients With Chronic Spontaneous Urticaria; Results Showed Rapid, Profound, Sustained Efficacy, Supporting Barzolvolimab’s Potential To Be A Transformational Therapy In CSU

Morgan Stanley Maintains Overweight on Celldex Therapeutics, Raises Price Target to $50

Celldex to Present at Upcoming Investor Conference

Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter Results

Is Celldex Therapeutics’ (CLDX) Growing Losses With Minimal Revenue a Strategic Bet or Structural Concern?